Side Effects of Micafungin
Micafungin is generally well-tolerated with a favorable safety profile, but common side effects include gastrointestinal symptoms (nausea, diarrhea, vomiting), phlebitis at infusion sites, liver enzyme elevations, electrolyte abnormalities (particularly hypokalemia and hypomagnesemia), and fever. 1
Most Common Side Effects by Clinical Setting
In Candidemia/Invasive Candidiasis Treatment
The most frequently reported adverse reactions in adults include:
- Gastrointestinal: Nausea (10%), diarrhea (11%), vomiting (13%), abdominal pain (4%)
- Hepatic: Abnormal liver tests (4%), increased AST (3%), increased alkaline phosphatase (3%)
- Infusion-related: Phlebitis (common, particularly with peripheral IV access) 1
In Esophageal Candidiasis Treatment
When using higher doses (150 mg/day), the following occur more frequently:
- Vascular: Phlebitis (19% vs 5% with fluconazole)
- General: Pyrexia/fever (13%)
- Gastrointestinal: Diarrhea (10%), nausea (8%), vomiting (7%)
- Dermatologic: Rash (5%)
- Neurologic: Headache (9%) 1
In Prophylaxis for Stem Cell Transplant
In this setting with prolonged use (median 18 days), nearly all patients experience adverse events, though most are related to underlying disease:
- Gastrointestinal: Diarrhea (77%), nausea (71%), vomiting (66%), abdominal pain (26%)
- Hematologic: Neutropenia (75%), thrombocytopenia (75%)
- Cardiac: Tachycardia (26%)
- Neurologic: Headache (44%), insomnia (37%)
- Dermatologic: Rash (25%) 1
Pediatric-Specific Side Effects
In children, the adverse event profile is similar but with some differences in frequency:
- Most common (≥15%): Vomiting (31%), diarrhea (22%), pyrexia (22%), nausea (19%), abdominal pain (16%), thrombocytopenia (15%)
- Hepatic: Mild ALT/AST elevations (significantly higher than historical controls but generally not clinically significant) 1, 2
- Electrolyte: Mild hypomagnesemia 3
Importantly, pediatric patients showed lower discontinuation rates (4-7%) compared to comparator drugs 1.
Serious but Less Common Adverse Effects
Hypersensitivity Reactions
- Anaphylaxis and anaphylactoid reactions including shock can occur (rare)
- Patients should be monitored during infusion 1
Hepatic Effects
- Hepatic impairment, hepatitis, or worsening hepatic failure
- Abnormal liver function tests are common (2-4%), but severe hepatotoxicity is uncommon
- In high-dose studies (300 mg/day), hepatobiliary adverse events occurred in 58% of patients but were generally manageable 4
Hematologic Effects
- Acute intravascular hemolysis, hemolytic anemia, and hemoglobinuria (rare)
- More common in patients with underlying hematologic conditions 1
Renal Effects
- Elevations in BUN and creatinine
- Renal impairment or acute renal failure
- Elderly patients showed higher incidence of renal impairment (1%) compared to younger adults (0.1%) 5
- Important distinction: Micafungin causes significantly less nephrotoxicity than amphotericin B 3
Comparative Safety Profile
Micafungin demonstrates superior tolerability compared to amphotericin B, with no additional drug side effects except mild hypomagnesemia, while amphotericin B causes significant increases in blood urea nitrogen 3. Compared to fluconazole, micafungin has a similar overall adverse event rate but higher rates of phlebitis (19% vs 5%) 1.
The pooled analysis of 3,028 patients across 17 clinical trials confirmed that treatment-related adverse events showed no clear association with higher doses or longer treatment duration 5. Even at high doses (300 mg/day), micafungin was safe and well-tolerated with infrequent serious adverse events or treatment discontinuation 4.
Key Clinical Considerations
- Drug-drug interactions are minimal compared to azoles, making micafungin particularly useful when patients are on medications metabolized by CYP3A4 6, 7
- Discontinuation rates are low: 4-7% in most studies 1
- No dose adjustment needed for renal or mild-to-moderate hepatic impairment
- Phlebitis risk can be minimized by using central venous access when possible
- Monitor liver enzymes periodically, especially with prolonged therapy or in patients with baseline hepatic dysfunction
Embryo-Fetal Toxicity Warning
Pregnant women and females of reproductive potential should be advised of potential risks to the fetus and should inform their healthcare provider of known or suspected pregnancy 1.